Divi's Laboratories delivered robust financial results for the quarter ended March 2026, with consolidated net profit rising 13.44% to ₹751 crore compared to ₹662 crore in the corresponding quarter of the previous year. According to reports from CNBC TV18 and Business Standard, the pharmaceutical company's revenue from operations grew 9.52% to ₹2,831 crore in Q4 FY26, up from ₹2,585 crore in Q4 FY25. The company's consolidated total income reached ₹2,986 crore for the quarter ended March 31, 2026, compared to ₹2,671 crore for the corresponding quarter of the previous year. The company's operating profit margin (OPM) improved to 32.99% in the current quarter from 34.27% in the previous year quarter. Notably, PAT surged 28.82% sequentially from ₹583 crore in Q3 FY26, while topline increased 8.72% quarter-on-quarter versus ₹2,585 crore in Q3 FY26. Earnings per share increased to ₹28.31 from ₹24.93 in the year-ago quarter. The results beat the CNBC-TV18 poll estimate of ₹713 crore, demonstrating strong operational performance.
For the full financial year 2026, Divi's Laboratories demonstrated strong performance across key metrics. As reported by The Economic Times, annual net profit increased 17.21% to ₹2,568 crore compared to ₹2,191 crore in FY25. The company's annual sales rose 12.82% to ₹10,560 crore in FY26, up from ₹9,360 crore in the previous financial year. Annual consolidated total income reached ₹11,067 crore compared to ₹9,712 crore in FY25. The PBDT (Profit Before Depreciation and Tax) for FY26 stood at ₹3,925 crore, representing an 18% increase from ₹3,318 crore in FY25. Profit Before Tax (PBT) for FY26 reached ₹3,388 crore after accounting for labour codes impact of ₹74 crore, showing a significant 19% growth from ₹2,916 crore in the previous financial year.
The company's EBITDA came in at ₹934 crore in Q4 FY26 against ₹886 crore in Q4 FY25, representing a growth of 5.4% year-on-year. According to CNBC TV18, EBITDA margin was at 33% in the reporting quarter against 34.3% in the year-ago period, with CNBC-TV18 estimates pegging margins at 34.2%. This margin compression reflects the company's operational challenges despite strong revenue growth. Profit Before Tax (PBT) for the quarter amounted to ₹963 crore as against ₹864 crore for the corresponding quarter of the previous year. The strong profitability trend indicates the company's operational efficiency and market positioning during the reporting period.
The company has announced a final dividend of ₹30 per equity share for FY26, subject to approval at the 36th Annual General Meeting with record date set for July 24, 2026. According to The Economic Times and Business Standard, expenses increased to ₹2,023 crore in Q4 FY26 from ₹1,838 crore in Q3 FY26 and ₹1,807 crore in Q4 FY25, covering materials consumed, purchases of stock-in-trade, employee benefits and finance costs. The company benefited from forex gains of ₹90 crore in Q4 FY26 compared to ₹10 crore in the corresponding quarter of the previous year. For the full financial year, forex gains totaled ₹211 crore against ₹48 crore in the previous year. The 36th AGM will be held on August 10, 2026, with the dividend payment to be made within specified timelines from the conclusion of the AGM.
Shares of Divi's Laboratories ended at ₹6,885 on Friday, up ₹24.80 or 0.36% from the previous close of ₹6,860.20 on the BSE, as reported by ET Now and Business Standard. The positive market response reflects investor confidence in the company's strong quarterly performance and dividend announcement. The company's consistent growth trajectory across key financial metrics, combined with the substantial dividend declaration, has contributed to the positive investor sentiment in the pharmaceutical sector. On a year-to-date basis, Divi's Lab share price has gained nearly 9%, while over the one-year period from May 23, 2025 to May 23, 2026, the stock price rose around 7%. Over the five-year period from May 23, 2021 to May 23, 2026, Divi's Labs stock surged nearly 69%.
